Lenalidomide news

All news on Lenalidomide (also known as Revlimid): plants, production capacities, investments and involved companies.

29 June 2026

Genmab: EPCORE DLBCL-4 shows PFS benefit for epcoritamab plus lenalidomide

Phase 3 topline: fixed‑duration subcutaneous epcoritamab + lenalidomide significantly reduced progression/death versus R‑GemOx in relapsed/refractory DLBCL; safety consistent with known profiles.
13 June 2026

Johnson & Johnson: TALVEY plus DARZALEX FASPRO shows superior PFS and OS in Phase 3 MonumenTAL‑3

GPRC5D bispecific plus anti‑CD38 combo cut progression risk and delivered 24‑month PFS up to 81% and OS up to 89% in earlier‑line relapsed/refractory multiple myeloma.
11 June 2026

Genmab: Epcoritamab plus R2 shows consistent benefit across EPCORE FL‑1 subgroups

Post‑hoc subgroup analysis of the Phase 3 EPCORE FL‑1 shows epcoritamab+rituximab+lenalidomide delivers consistent PFS, ORR and CRR gains with a manageable safety profile across risk and fitness subgroups.
29 May 2026

Johnson & Johnson: TECVAYLI improves PFS and OS in second-line multiple myeloma

Phase 3 MajesTEC‑9: teclistamab cut progression/death risk 71% (HR 0.29) and death 40% (HR 0.60) vs PVd/Kd in early RRMM; higher ≥CR (65.9% vs 16.8%); infections and CRS increased
17 February 2026

Genmab Releases 2025 Annual Report

The report highlights 2025 achievements, financials, and 2026 outlook, including revenue growth, strategic acquisitions, and regulatory approvals.
16 January 2026

Genmab Reports Phase 3 Trial Results for Epcoritamab in Relapsed/Refractory DLBCL

Epcoritamab shows improved progression-free survival in Phase 3 trial for R/R DLBCL. Safety profile consistent. Further analysis and regulatory discussions planned.

Who will be producing Lenalidomide in the future?

Find out with chemXplore Alpha

Learn more